Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

Yonsei University107 enrolled

Overview

This study aims to investigate the effect of involved-field radiotherapy for recurrent ovarian cancer after primary standard treatment. We will investigate whether the addition of involved-field RT improves 2-year PFS in those patients than that of historical data (only with other standard salvage treatments as systemic chemotherapy ± maximum tumor resection).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

107

Conditions

Recurrent Ovarian Cancer

Interventions

Involved-field radiotherapyRADIATION

After the diagnosis of recurrences, patients will receive involved-field radiotherapy (gross tumor volume + margin) with any radiation dose scheme (≥45 Gy Biological Equivalent dose) as physician's discretion.

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathologically confirmed ovarian carcinoma * Patients who received "standard treatment" for each stage as a primary treatment * No. of recurrent lesions: If, all in lung, or intra-abdominal or pelvis organs - ≤ 5 If, any in liver, bone, or spinal cord - ≤ 2 * Size of recurrent lesions ≤5 cm * All recurrent lesions are available for involved-field radiotherapy * Within 60 days before enrollment: * Absolute neutrophil count ANC ≥ 500 / mm3 * Platelet ≥ 50,000 / mm3 * Hb ≥ 8.0 g / dl * Good performance status (ECOG 0-1) Exclusion Criteria: * Brain metastasis * Diffuse peritoneal carcinomatosis * Malignant pleural effusion * History of previous salvage radiotherapy for recurrent lesions * History of other malignancy or severe/unstable medical condition

Locations (1)

Severance Hospital

Seoul, Korea, South Korea

RECRUITING